Lucida Medical provides Pi™, an AI‑driven decision‑support platform that analyzes prostate MRI scans to detect clinically significant cancers with sensitivity and specificity comparable to expert radiologists. By delivering real‑time risk scores, automated lesion segmentation, and standardized reports that integrate with existing PACS and RIS systems, Pi™ enables same‑day biopsy scheduling for high‑risk patients, reducing diagnostic delays, unnecessary procedures, and overall pathway costs.
Funding
$517.8K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TFFounders
Product
Problem
Prostate cancer diagnosis often requires multiple separate appointments for MRI imaging and subsequent biopsy, leading to delayed treatment decisions, increased patient anxiety, and higher healthcare costs. Variability in radiologist interpretation can also affect the detection of clinically significant cancers.
Solution
Lucida Medical offers Pi™, an AI-driven decision‑support platform that analyzes prostate MRI scans to identify clinically significant cancers with sensitivity and specificity comparable to expert radiologists. The system provides real‑time risk assessments that enable clinicians to schedule same‑day biopsies for high‑risk patients, streamlining the diagnostic pathway. Pi™ integrates with existing radiology workflows, delivering automated lesion segmentation, standardized reporting, and actionable recommendations. By reducing unnecessary biopsies and accelerating treatment planning, the platform helps lower overall pathway costs while maintaining diagnostic quality.
Target Audience
Primary customers are urologists, radiologists, and prostate cancer care teams in hospitals and diagnostic centers seeking to accelerate and standardize the prostate cancer diagnostic workflow.
Features
- Deep‑learning algorithms trained on large, multi‑institutional datasets to detect and grade prostate lesions on MRI
- Automated lesion segmentation and volumetric analysis with visual overlays for radiologist review
- Quantitative risk scores that prioritize patients for immediate same‑day biopsy versus surveillance
- Seamless integration with PACS and radiology information systems via standard DICOM and HL7 interfaces
- Dashboard for clinicians showing sensitivity, specificity, and confidence metrics alongside patient history
- Continuous model updates validated through peer‑reviewed publications (e.g., European Radiology)